Background-Many myocardial infarctions and strokes occur in individuals with low-density lipoprotein cholesterol levels below recommended treatment thresholds. High sensitivity C-reactive protein (hs-CRP) testing has been advocated to identify low-and intermediate-risk individuals who may benefit from statin therapy. Methods and Results-A decision analytic Markov model was used to follow hypothetical cohorts of individuals with normal lipid levels but without coronary artery disease, peripheral arterial disease, or diabetes mellitus. The model compared current Adult Treatment Panel III practice guidelines, a strategy of hs-CRP screening in those without an indication for statin treatment by current practice guidelines followed by treatment only in those with elevated hs-CRP levels, and a strategy of statin therapy at specified predicted risk thresholds without hs-CRP testing. Risk-based treatment without hs-CRP testing was the most cost-effective strategy, assuming that statins were equally effective regardless of hs-CRP status. However, if normal hs-CRP levels identified a subgroup with little or no benefit from statin therapy (Ͻ20% relative risk reduction), then hs-CRP screening would be the optimal strategy. If harms from statin use were greater than generally recognized, then use of current clinical guidelines would be the optimal strategy. Conclusion-Risk-based statin treatment without hs-CRP testing is more cost-effective than hs-CRP screening, assuming that statins have good long-term safety and provide benefits among low-risk people with normal hs-CRP. (Circulation.
T he indications for statin use have expanded in the past 2 decades from secondary prevention in patients after acute myocardial infarction (MI) to primary prevention among individuals at high predicted cardiovascular risk. 1 Better strategies to prevent cardiovascular disease in intermediate-and low-risk populations are needed because many MIs and strokes occur in individuals with low-density lipoprotein cholesterol below currently recommended treatment thresholds. 2 Some clinicians believe that the relative risk reductions by statins documented in high-risk populations can be achieved in intermediate-and low-risk populations. 3 Three recent cost-effectiveness analyses suggest that extending statin therapy to relatively younger and healthier individuals (10- year Framingham risk as low as 5%), regardless of lipid levels, might be cost-effective. 4 -6 However, widespread statin use in this population may not be feasible because of its cost and concerns about potential adverse effects. An alternative strategy is to use an additional cardiovascular risk marker such as serum high-sensitivity C-reactive protein (hs-CRP) level to identify intermediate-and low-risk individuals who would benefit from statin therapy.
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A recent randomized controlled trial (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin [JUPITER]) showed that rosuvastatin reduced the risk of cardiovascular events in individuals with low-density lipoprotein cholesterol Ͻ130 mg/dL and an elevated hs-CRP. 7 Although JUPITER did not randomize patients to hs-CRP testing, it suggests that screening individuals for an elevated hs-CRP might be an effective strategy for improving primary prevention. We developed a decision analytic model to examine the cost-effectiveness of hs-CRP screening compared with current clinical practice guidelines for statin therapy and an alternative strategy of statin therapy based on predicted cardiovascular risk without hs-CRP testing.
Methods
We performed a cost-effectiveness analysis following the recommendations from the Panel on Cost-Effectiveness in Health and Medicine by adopting a societal perspective and applying a 3% annual discount rate on costs and health benefits. 8 The results of the analysis are expressed in terms of monetary costs (2008 US dollars), quality-adjusted life-years (QALYs), and incremental costeffectiveness ratios. We define the optimal or most cost-effective strategy as having the highest QALY benefit with an incremental cost-effectiveness ratio less than the willingness-to-pay threshold.
Decision Model
We constructed a Markov model 9 of cardiovascular disease to assess the clinical and economic consequences of the 3 strategies ( Figure  1 ). The model follows hypothetical cohorts, starting at 40 years of age, with normal lipid levels and no clinical evidence of coronary artery disease, peripheral arterial disease, or diabetes mellitus. We built the model using TreeAge Pro 2008 (TreeAge Software, Inc, Williamstown, Mass).
We modeled the status quo as full adherence to current guidelines from the Adult Treatment Panel III (ATP-III), 1 which recommend statin therapy for primary prevention for individuals with a 10-year Framingham predicted risk for coronary events of Ͼ20% or with diabetes mellitus. In the hs-CRP screening strategy, we assumed that screening for elevated hs-CRP levels would be added to basic cardiovascular risk assessment starting at a specific age in those without an indication for statin treatment by ATP-III guidelines and that treatment would be initiated after finding an hs-CRP level of Ն2.0 mg/L. 7 We assumed that individuals with an initial hs-CRP of Ͻ2.0 mg/L at initial screening would undergo additional screening annually thereafter. We also tested an alternative strategy of starting statin treatment in all individuals at or above specific predicted risk thresholds estimated by the 10-year Framingham risk score for coronary events without conducting hs-CRP screening. We refer to this strategy as risk-based treatment without hs-CRP testing. In all 3 strategies, all individuals had a baseline risk assessment based on the traditional cardiovascular risk factors of age, sex, blood pressure, diabetes mellitus, lipid levels, and smoking status.
We created hypothetical cohorts with different baseline cardiovascular risk levels based on Framingham risk factors, which differed by sex, systolic blood pressure, hypertension medication use, and smoking status ( Table I in the online-only Data Supplement) . Lipid levels in all cohorts were assumed to be the median levels of the JUPITER population: total cholesterol of 186 mg/dL, low-density lipoprotein cholesterol of 108 mg/dL, and high-density lipoprotein cholesterol of 49 mg/dL. 7
Data and Sources
We derived values for model parameters (Table 1 ) from the medical literature. We estimated age-and sex-specific noncardiovascular 
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Cost-Effectiveness of hs-CRP Screening mortality using the 2004 US Life Tables 10 and age-and sex-specific MI and stroke rates using the Framingham risk models for coronary artery disease 1 and stroke. 11 We estimated the morbidity and mortality caused by cardiovascular events using Medicare data and community-based studies. [12] [13] [14] [15] [16] [17] [18] We used the Reynolds Risk Score 19, 20 and hs-CRP population distributions 21, 22 to adjust the Framingham risk for normal or elevated hs-CRP levels compared with an unknown hs-CRP level. Further details are provided in the onlineonly Data Supplement.
Statin Effectiveness and Adherence
To account for the possibility that the effectiveness of statin therapy might vary according to hs-CRP levels, we included 2 scenarios: the equal-effects scenario and the differential scenario. In the equaleffects scenario, we assumed that the relative risk reductions from statin use were independent of hs-CRP levels and Framingham risk factors and that statin therapy reduced the risk of MI by a factor of 0.77 and the risk of stroke by 0.83 based on the results of a meta-analysis of 14 randomized controlled trials of statins in intermediate-and high-risk populations. 23 In the differential scenario, we assumed that baseline hs-CRP levels modified the efficacy of statin treatment, so individuals with an elevated hs-CRP would have relative risks of 0.46 for MI and 0.52 for stroke as seen in JUPITER, 7 whereas individuals with normal hs-CRP levels would have no reduction in cardiovascular risk from statin therapy ( Table  1 ). In an additional hypothetical scenario, we assumed that hs-CRP screening would increase adherence to statin medication among individuals with elevated hs-CRP levels.
Statin Harms
Statins cause minor side effects such as muscle pain in Ϸ15% to 20% of initial users. 24, 25 We assumed that 17.5% of eligible individuals would stop statin use within 6 months because of intolerance. 25 In sensitivity analyses, we also analyzed the effect of having statin users incur a small utility decrement from minor side effects or the inconvenience of taking a daily medication. In all scenarios, we assumed that rhabdomyolysis and renal failure would occur at a rate of between 5 and 30 people per 1 million prescriptions, equivalent to about 1 event per 18 000 patient-years of use. 26 In addition, because of a recent study, 27 we modeled a possible increased risk of new-onset diabetes mellitus resulting from statin therapy. Finally, we performed a sensitivity analysis of the possibility that long-term statin therapy might increase the risk of rare but fatal diseases.
Costs and Quality of Life
We included age-specific baseline costs of health care 28 and a 1-time, age-specific cost of end-of-life care in the year of death 29 for all individuals in the model. Other costs were based on 2008 Medicare reimbursement rates or literature reports ( Table 1) . We assumed the cost of statin therapy to be that of generic simvastatin 80 mg/d, which is $1.10/d. 30 In sensitivity analysis, we varied statin costs from $0.25/d to more than $3.85/d, the cost of branded rosuvastatin. 30 We used age-specific quality-of-life values derived from the Medical Expenditure Panel Survey 31 adjusted by weights for cardiovascular health states (Table 1 ).
Probabilistic Sensitivity Analysis
We conducted 1-way, multiway, and probabilistic sensitivity analyses to evaluate the effects of model uncertainties using ranges (Table  1) and distributions ( Table VI in 
Results

Model Validation
The model results agreed well with cardiovascular mortality from the United States Life Tables for 2004 10 and the overall mortality rate in JUPITER. 7 For a cohort of 40-year-old men with hypertension, the model estimated total life expectancy within 4.2% of the United States Life Tables and cardiovascular mortality within 1.6%. For a cohort similar to the JUPITER population (men from 66 to 68 years of age with a 10-year Framingham risk of 10%) and assuming the relative risk reductions from statin use reported by the trial, our model predicted a relative risk of 0.85 for total mortality in the statin arm, close to the relative risk of 0.80 observed in JUPITER; the difference may be due to limitations of the Framingham model as applied to the non-US JUPITER participants. 32
Comparison of Strategies: Equal-Effects Scenario
Use of the current ATP-III guidelines resulted in the lowest costs and fewest QALYs among both men and women and in each risk category (Tables VII and VIII and Figure IIa in the online-only Data Supplement). Risk-based treatment without hs-CRP testing led to the highest costs and the most QALYs for all risk levels in both men and women, whereas the hs-CRP screening strategy led to intermediate costs and QALYs. Risk-based treatment without hs-CRP testing was the optimal strategy for both men and women at nearly all risk levels (Figure 2A , Table 2 , and Figure IIa in the online-only Data Supplement), even though hs-CRP screening was cost- 
Scenarios Involving Statin Harms
Model results were very sensitive to potential harms from statin therapy. A small quality-of-life decrement of 1% to 2% among statin users would make hs-CRP screening optimal ( Figure 3 ). However, a slightly greater quality-of-life decrement of 2% to 3% would make the ATP-III guidelines most cost-effective. A small increase in the annual risk of diabetes mellitus from statin therapy would make hs-CRP screening the optimal strategy, but a greater increase in diabetes risk would make ATP-III guidelines optimal (Table 3) . A similar pattern was seen with increasing risk of a rare but fatal adverse event from statin therapy ( Table 3 ).
Scenarios Involving Differential Statin Effectiveness and Adherence
We examined the possibility that the effectiveness of statins might vary with hs-CRP levels by assuming that statin therapy benefited individuals with elevated hs-CRP levels but did not benefit those with normal hs-CRP levels. In this differential scenario, hs-CRP screening was the optimal strategy for both men and women in nearly all risk categories and willingnessto-pay thresholds ( Figure 2B , Table 2 , and Figure IIB and Tables IX and X in the online-only Data Supplement). We assessed the degree of treatment effect modification from hs-CRP status that would make hs-CRP screening the optimal strategy by assuming the relative risks from statin therapy seen in JUPITER for hs-CRP positive individuals (0.46 for MI and 0.52 for stroke) and then varying the relative risks from statin therapy in hs-CRP-negative individuals. Statin therapy in hs-CRP-negative individuals would need to provide little or no benefit, a relative risk reduction of less than Ϸ20%, for hs-CRP screening to be optimal at a willingness-to-pay threshold of $50 000 per QALY (Table 4 ). For an example of a man with hypertension only, the relative risk reduction from statins would have to be Յ15% in those with normal hs-CRP as opposed to Ϸ50% in those with elevated hs-CRP for hs-CRP screening to be the optimal strategy. We modeled the possibility that some patients started on statins through risk-based treatment without hs-CRP testing would not adhere to therapy, whereas those started on statins through a strategy of hs-CRP screening would be fully adherent. Noncompliance with statin therapy would have to be Ͼ30% to 40%, depending on the risk group, for hs-CRP screening to be the optimal strategy (Table 5 ).
Other Sensitivity Analyses
Increasing the cost of statin medication would make all 3 strategies less cost-effective. A statin cost of $3.85/d, the cost of rosuvastatin, would make ATP-III guidelines the most cost-effective strategy at a $50 000-per-QALY willingnessto-pay threshold (Figure 4 ). Hs-CRP screening was the optimal strategy when statins cost between $2/d and $3/d. Risk-based treatment without hs-CRP testing was the preferred strategy for most risk groups with statin costs of Ͻ$2/d.
Altering other input variables within reasonable ranges in 1-way sensitivity analyses did not change the optimal strate- *Optimal strategy is defined as the nondominated strategy with the highest QALY benefit that has an incremental cost-effectiveness ratio less than $50 000/QALY. †Equal-effects scenario assumes equal risk reduction from statin therapy regardless of hs-CRP status. ‡Differential scenario assumes that statin therapy reduces risk in only those with an elevated hs-CRP.
§"Treatment" refers to statin treatment at that risk profile without hs-CRP testing. Figure 3 . Optimal strategy given a quality-of-life decrement for statin use at a willingness-to-pay threshold of $50 000/QALY, assuming equal effectiveness of statin therapy across various hs-CRP levels. *Assumes a willingness-to-pay threshold of $50 000/QALY. †hs-CRP screening is already the optimal strategy in the base case.
Lee et al Cost-Effectiveness of hs-CRP Screening
gies. Of note, we conducted sensitivity analyses of various definitions of an elevated hs-CRP level and different screening intervals. Increasing the threshold from 2.0 to 10 mg/L made hs-CRP screening less favorable. Decreasing the frequency of hs-CRP testing from annual testing to every 5 years, every 10 years, or a 1-time screening did not change any of the optimal strategies. Probabilistic sensitivity analysis identified the greatest uncertainty around the costeffectiveness estimates to be in the lowest-risk groups ( Figure  Ia and Ib in the online-only Data Supplement).
Interactive Web-Based Presentation
An interactive presentation of the model results, which allows users to enter patient risk factors and other inputs, is available at http://med.stanford.edu/hsr/crp-screening.
Discussion
The cost-effectiveness of a preventive therapy aimed at a large population depends on its being safe, effective, and relatively inexpensive. Current ATP-III guidelines recommend statin therapy for primary prevention only among individuals at high risk for cardiovascular events. Among individuals without an indication for statin treatment by ATP-III guidelines, our analysis suggests that a strategy of hs-CRP screening, with treatment only for those with elevated hs-CRP levels, would improve outcomes at an acceptable cost (Figure 2A and Figure IIa in the online-only Data Supplement). However, initiation of statin treatment at lower risk levels without hs-CRP testing would further improve clinical outcomes at acceptable cost, making it the optimally cost-effective strategy in our analysis. This strategy of riskbased treatment without hs-CRP testing is preferred as long Hypertension and smoking Ն0.87
*Assumes a willingness-to-pay threshold of $50 000/QALY and relative risks from JUPITER for those who are hs-CRP positive of 0.46 for MI and 0.52 for stroke.
†The relative risks of MI and stroke in those with normal hs-CRP are made equal for the purposes of constraining the many possible degrees of variation. Hypertension and smoking Ն0.33
*Assumes a willingness-to-pay threshold of $50 000/QALY and complete adherence in those who test hs-CRP positive in the hs-CRP screening strategy.
†hs-CRP screening is already the optimal strategy.
as statins have good long-term safety and provide benefits even in low-risk people with normal hs-CRP levels.
Our results were particularly sensitive to increased risk of long-term harms from statin therapy, including frequent low-intensity muscle soreness, diabetes mellitus, 27 and potentially fatal diseases such as liver failure or cancer. 33 Within a narrow range of increased risk of these adverse events, hs-CRP screening would be more favorable than risk-based treatment without hs-CRP testing ( Table 3 and Figure 3 ), but at higher risk of adverse events, the current ATP-III guidelines would be the optimal strategy. The implication of this finding is that even a small increase in harms, whether physical or psychological, would outweigh the benefits of statin treatment among low-risk individuals. A meta-analysis of randomized studies showed that a possible excess incidence of diabetes mellitus in statins users might be as much as 0.1% annually. 27 If this degree of harm is real, it could change the recommended strategy in our model for the lowest-risk individuals ( Table 3) .
The ability of a marker such as an elevated hs-CRP level to identify increased risk does not necessarily imply that screening with the risk marker is cost-effective. 34 If an elevated hs-CRP simply indicates increased risk, our analysis suggests that hs-CRP screening would not be cost-effective. However, if hs-CRP levels could identify people for whom statin therapy would not be effective in reducing risk, and thereby spare them from unnecessary treatment, then hs-CRP screening would be a cost-effective strategy. There are very few markers in cardiovascular medicine that separate treatment responders from nonresponders, such as ST-segment elevation during acute MI as an indicator of benefit from emergency coronary reperfusion. Most treatments reduce risk proportionally across multiple subgroups defined by clinical or laboratory measures. Proof that a factor is a treatmenteffect modifier is provided by a statistical test for interaction between treatment and that factor. There is some evidence that hs-CRP may be a special case of a factor that can detect nonresponsiveness to statin therapy. In the Air Force/Texas Coronary Atherosclerosis Prevention randomized controlled trial, 35 lovastatin reduced the relative risk of a coronary event by a factor of 0.58 (95% confidence interval, 0.34 to 0.98) for the subgroup with CRP levels above the median compared with 1.08 (95% confidence interval, 0.56 to 2.08) for the subgroup with CRP levels below the median. The wide confidence limits on the estimate in the low CRP group included the overall trial result of 0.63. Furthermore, the formal statistical test for interaction between CRP level and lovastatin treatment was not significant (Pϭ0.06). In a similar retrospective reanalysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure, rosuvastatin reduced the relative risk of the primary end point by a factor of 0.87 (95% confidence interval, 0.77 to 0.98) for the subgroup with hs-CRP Ն2.0 mg/L compared with 1.09 (95% confidence interval, 0.89 to 1.34) in those with hs-CRP Ͻ2.0 mg/L. 36 The statistical test for an interaction of hs-CRP with treatment in this study was also not significant (Pϭ0.062), with the confidence limits including the overall trial result of 0.92. In JUPITER, there was no significant interaction of hs-CRP levels with treatment (Pϭ0.15). 37 For hs-CRP screening to be the most cost-effective strategy, the relative risk reduction from statin therapy in those with normal hs-CRP levels must be substantially less than in those with elevated hs-CRP: Ͻ 20% versus Ͼ50% (Table 4) . Although JUPITER showed a 50% relative risk reduction in people with elevated hs-CRP, its early termination may have overestimated treatment effect. 38 In addition, because the confidence intervals from available studies encompass broad relative risk reductions for those with elevated and normal hs-CRP levels, the current data are not sufficient to conclude that hs-CRP levels are able to identify this great difference of treatment effectiveness. Our findings suggest that this question should be studied further, possibly using stored serum samples from other statin trials, in light of its pertinence to the strategy of hs-CRP screening to guide statin use.
Aside from selecting individuals who are particularly responsive to statin therapy, hs-CRP screening might theoretically improve adherence among low-risk individuals. Data from a randomized control trial of coronary artery calcium screening suggest that the knowledge of an additional risk marker does not improve medication adherence among lowrisk patients. 39 There are no data showing that awareness of hs-CRP results improves adherence to statin therapy. However, only a relatively small trial would be needed to test the hypothesis because a large effect (Ն29% improvement in adherence) is required to make hs-CRP screening the optimal strategy ( Table 5 ).
The results of our analysis were somewhat sensitive to the cost of statin therapy (Figure 4 ). Risk-based treatment without hs-CRP testing was the most cost-effective strategy for statin costs of less than $2/d. With increased availability of low-cost statins and with approaching patent expirations for atorvastatin (June 2011) and rosuvastatin (January 2016), 40 prices of statins are unlikely to exceed the threshold needed to make hs-CRP screening the optimal strategy in the equaleffects scenario.
Recent studies have suggested that statin treatment for those with a 10-year Framingham risk in the range of 5% might be cost-effective regardless of lipid levels. 4 -6 Our results are consistent with these studies but provide a more comprehensive view of treatment strategies by incorporating hs-CRP screening scenarios.
Study Limitations
The major limitations of this study are the uncertainties of important model parameters that greatly affect the results. In particular, the effectiveness of statin therapy in those with normal hs-CRP and the potential long-term harms from statins are not fully known. A study using National Health and Nutrition Examination Survey data suggests that an additional 6.5 million people in the United States would be recommended for statin therapy with a strategy of hs-CRP screening compared with current ATP-III guidelines. 41 With the use of the population distribution of hs-CRP cited in that study, an additional 12.7 million people would qualify for statin therapy using a risk-based treatment strategy without hs-CRP screening compared with current ATP-III guidelines. In light of the large number of people potentially affected by these strategies, the effectiveness of statin therapy in those
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Conclusions
Statin treatment of intermediate-to low-risk men and women at specific predicted cardiovascular risk thresholds without hs-CRP testing appears to be the optimal primary prevention strategy, assuming that statin therapy is relatively safe, inexpensive ($1.10/d or less), and effective regardless of hs-CRP status and cardiovascular risk level. Convincing evidence that a normal hs-CRP level identifies individuals who would receive little or no benefit from statin therapy would favorably alter the cost-effectiveness of hs-CRP screening. Any potential harms from statin use beyond those currently recognized would offset the potential benefits of lowering the current ATP-III guidelines risk thresholds for statin treatment. 
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